| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
MNS (NSC170724; NSC-170724; NSC 170724; 5-(2-Nitrovinyl)benzodioxole)) is a novel, potent and selective TKI-tyrosine kinase inhibitor with anti-platelet activity. It has an IC50 of 2.5 μM, 29.3 μM, and 1.7 μM for several kinases, including Syk, Src, and p97, respectively, and inhibits them all.
| Targets |
p97 ( IC50 = 1.7 μM ); Syk ( IC50 = 2.5 μM ); HDAC4 ( IC50 = 510 nM ); Src ( IC50 = 29.3 μM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
MNS (3,4-methyl-enedioxy-β-nitrostyrene) completely inhibits 2 μM U46619-(a thromboxane A2 mimic), 5 μM ADP-, 100 μM arachidonic acid-(AA), 10 μg/ml collagen-, and 0.1 U/ml thrombin-induced platelet aggregation in a concentration-dependent manner with IC50 of 2.1 μM, 4.1 μM, 5.8 μM, 7.0 μM, and 12.7 μM, respectively. MNS inhibits platelet aggregation caused by either the calcium ionophore A23187 (1 μM) or the protein kinase C (PKC) activator PDBu (200 nM) with IC50 of 25.9 μM and 4.8 μM, respectively. MNS (20 μM) decreases dthrombin-induced P-selectin expression on platelets to levels comparable to those observed in PGE1-treated platelets. MNS (20 μM) markedly inhibits thrombin-but not PDBu-induced MARCKS phosphorylation in platelets. MNS (20 μM) markedly inhibits protein tyrosine phosphorylation at either 0.5 min or 3 min after thrombin or collagen stimulation in platelets. MNS stimulates UbG76V-GFP and ODD-Luc degradation with IC50 of 1.6 μM and 5.9 μM, respectively. MNS inhibits MG132-induced accumulation of the reporter with IC50 of 2.1 μM. MNS inhibits Gram-positive (Staphylococcus aureus and Enterococcus faecalis) and Gram-negative (Escherichia coli and Pseudomonas aeruginosa) bacteria with minimum inhibitory concentrations (MICs) of 128 mg/L. MNS is much more potent than genistein in inhibiting platelet aggregation and protein tyrosine phosphorylation. MNS (3,4-Methylenedioxy-β-nitrostyrene) is equally potent as inhibitors of platelet aggregation as 3,4-dimethoxy-β-nitrostyrene. MNS (20 μM) concentration-dependently prevents ATP release from platelets stimulated by thrombin or collagen. MNS (20 μM) inhibits thrombin-induced PAC-1 binding to human platelets.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C9H7NO4
|
|
|---|---|---|
| Molecular Weight |
193.16
|
|
| Exact Mass |
193.037
|
|
| Elemental Analysis |
C, 55.96; H, 3.65; N, 7.25; O, 33.13
|
|
| CAS # |
1485-00-3
|
|
| Related CAS # |
|
|
| PubChem CID |
672296
|
|
| Appearance |
Light yellow to green yellow solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
334.9±11.0 °C at 760 mmHg
|
|
| Melting Point |
159-163 °C
|
|
| Flash Point |
168.8±21.3 °C
|
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
|
| Index of Refraction |
1.640
|
|
| LogP |
2.27
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
1
|
|
| Heavy Atom Count |
14
|
|
| Complexity |
248
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=[N+]([O-])/C=C/C1=CC(OCO2)=C2C=C1
|
|
| InChi Key |
KFLWBZPSJQPRDD-ONEGZZNKSA-N
|
|
| InChi Code |
InChI=1S/C9H7NO4/c11-10(12)4-3-7-1-2-8-9(5-7)14-6-13-8/h1-5H,6H2/b4-3+
|
|
| Chemical Name |
5-[(E)-2-nitroethenyl]-1,3-benzodioxole
|
|
| Synonyms |
SYK Inhibitor III; MNS
|
|
| HS Tariff Code |
2934.99.03.00
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 39~50 mg/mL ( 201.9~258.9 mM )
H2O : ~0.7 mg/mL (~3.5 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (12.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 2% DMSO + corn oil: 5mg/ml |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1771 mL | 25.8853 mL | 51.7706 mL | |
| 5 mM | 1.0354 mL | 5.1771 mL | 10.3541 mL | |
| 10 mM | 0.5177 mL | 2.5885 mL | 5.1771 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05016765 | Completed | Device: Active, self-directed electrical stimulation of the median nerve |
Tic Disorder, Chronic Motor or Vocal Tourette Syndrome |
Washington University School of Medicine |
November 18, 2021 | Not Applicable |
| NCT02278068 | Completed | Device: Metabolic Neuromodulation System (MNS) |
Endocrine, Nutritional and Metabolic Diseases (E00-E89) Diabetes |
Metavention | October 2014 | Not Applicable |
| NCT02971371 | Completed | Device: Lokomat | Stroke | IRCCS Centro Neurolesi "Bonino-Pulejo" |
October 2015 | Not Applicable |
|
|---|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
